Ken Griffin Metacrine, Inc. Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.43 - $0.55 $58,740 - $75,133	136,606 New	136,606 $66,000
Q1 2022 May 16, 2022	BUY	$0.43 - $0.7 $11,382 - $18,530	26,472 Added 180.43%	41,144 $25,000
Q4 2021 Feb 14, 2022	SELL	$0.64 - $3.83 $11,364 - $68,009	-17,757 Reduced 54.76%	14,672 $9,000
Q3 2021 Nov 15, 2021	BUY	$2.61 - $3.84 $51,466 - $75,720	19,719 Added 155.15%	32,429 $111,000
Q2 2021 Aug 16, 2021	BUY	$3.37 - $5.73 $42,832 - $72,828	12,710 New	12,710 $48,000
Q4 2020 Feb 16, 2021	SELL	$7.75 - $11.42 $1.9 Million - $2.81 Million	-245,760 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$9.38 - $11.76 $2.31 Million - $2.89 Million	245,760 New	245,760 $2.49 Million

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.